Delving into the Latest Updates on AGN-241622 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

AGN 241622

Target

ADRA2

Action

agonists

Mechanism

ADRA2 agonists(Adrenergic receptors alpha-2 agonists)

Therapeutic Areas

Eye Diseases

Active Indication-

Inactive Indication

Presbyopia

Originator Organization

Allergan UC

Active Organization-

Inactive Organization

AbbVie, Inc.

License Organization-

Drug Highest PhaseDiscontinuedPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

A First-in-Human, Phase 1/2, Dose-ascending, Multicenter, Masked, Randomized, Vehicle-controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AGN-241622 in Healthy Participants and Participants With Presbyopia (Stage 1 and Stage 2) and Efficacy in Participants With Presbyopia (Stage 2)

The objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AGN-241622 ophthalmic solution for the first time in human participants

Start Date27 Jul 2020

Sponsor / Collaborator

AbbVie, Inc.

100 Clinical Results associated with AGN-241622

Login to view more data

100 Translational Medicine associated with AGN-241622

Login to view more data

100 Patents (Medical) associated with AGN-241622

Login to view more data

1

News (Medical) associated with AGN-241622

27 Jun 2023

·endpts.com

After cutting back on Vuity last fall, AbbVie culls a second-gen presbyopia eye drop

In 2021, AbbVie secured the first FDA approval for an eye drop for presbyopia, but in 2022 the drugmaker reduced sales and marketing on the product, branded as Vuity. Now, a second-gen attempt at treating the age-related farsightedness condition is going into the trash bin. The Chicago-area Big Pharma updated a federal trials database late last week to say it had terminated a Phase I/II study of AGN-241622. A proof-of-concept readout had been expected in 2023, per a corporate presentation earlier this year. Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Drug ApprovalClinical Study

100 Deals associated with AGN-241622

Login to view more data